Scott Chan

Scott Chan moved from China to the U.S. with family at the age of ten. He passed the rigorous entrance exam and attended the merit-based Stuyvesant High School, widely held to be best public school in New York City. He earned undergraduate degrees from New York University followed by an MBA degree from the Zicklin School of Business at Baruch College.

Shortly thereafter Scott partnered with Dr. Stephen Leeb on numerous financial publications. Today, he serves as the lead analyst for Real World Investing and The Complete Investor.

Mr. Chan is an avid baseball fan and enjoys outdoor activities in his spare time. A multicultural person, he reads Chinese and speaks fluent Mandarin and Cantonese Chinese.

Analyst Articles

Buy ViaSat, Inc. (Nasdaq: VSAT) and ChannelAdvisor (NYSE: ECOM). Today we are adding to the Brain Trust Profits portfolio two high-conviction picks from two top hedge funds. The first stock ViaSat (Nasdaq: VSAT) should be a familiar name to long-time subscribers. We found the stock in Seth Klarman’s Baupost Group… Read More

Sotheby’s (NYSE: BID) took a tumble after reporting disappointing second-quarter earnings. For the first time since February 2016, the stock fell in reaction to earnings. The company booked revenues of $314.9 million during the quarter, slightly below The Street’s expectation for $315.7 million. The roughly $315 million figure represents a… Read More

This week, Republic Services (NYSE: RSG) reported a 7.5 percent year-over-year revenue increase in the second quarter was the best growth rate in eight years. Earnings per share (adjusted for non-recurring items) of $0.61 was a 10.9 percent improvement over the second quarter of 2016. Average yield increased 2.5 percent,… Read More

This week our biotech pick Theravance Biopharma (Nasdaq: TBPH) announced the results of its 12-month long Phase 3 study of revefenacin (TD-4208), jointly conducted with Mylan (Nasdaq: MYL). As we discussed in the June 9 weekly issue, the results released earlier this year from the first two Phase 3 studies… Read More